Analyst Ratings For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
Today, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock was downgraded by HC Wainwright from Buy to Neutral with a price target of $1.00.
There are 4 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is Buy with a consensus target price of $3.00 per share, a potential 328.94% upside.
Some recent analyst ratings include
- 2/1/2019-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gets downgraded to Neutral by HC Wainwright with a price target of $1.00
- 1/31/2019-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had its Overweight rating reiterated by Piper Jaffray Companies with a $3.00 price target
- 1/8/2019-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has coverage initiated with a Buy rating and $5.00 price target
- 1/3/2019-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has coverage initiated with a Outperform ➝ Outperform rating and $3.00 price target
- 11/6/2018-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gets downgraded to Neutral by National Securities
- 10/6/2017-AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had its Buy rating reiterated by Seaport Global Securities
- On 12/21/2018 Peter J Barris, Major Shareholder, bought 500,000 with an average share price of $1.55 per share and the total transaction amounting to $775,000.00.
- On 12/10/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 170,400 with an average share price of $1.99 per share and the total transaction amounting to $339,096.00.
- On 12/6/2018 Peter W Sonsini, Major Shareholder, bought 27,300 with an average share price of $1.99 per share and the total transaction amounting to $54,327.00.
- On 11/30/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 96,400 with an average share price of $1.98 per share and the total transaction amounting to $190,872.00.
- On 11/28/2018 Peter W Sonsini, Major Shareholder, bought 24,500 with an average share price of $1.99 per share and the total transaction amounting to $48,755.00.
- On 11/21/2018 Anthony B Evnin, Director, bought 109 with an average share price of $2.05 per share and the total transaction amounting to $223.45.
- On 11/19/2018 Equity Opportunities Iv Growth, Major Shareholder, bought 1,200,000 with an average share price of $1.86 per share and the total transaction amounting to $2,232,000.00.
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Recent Trading Activity for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
Shares of AVEO Pharmaceuticals, Inc. closed the previous trading session at 0,70 −1,07 60,49 % with shares trading hands.